Holen Sie sich die Stockscreener-App
4.25
0.00%
0.00
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Relmada Therapeutics Announces Urology Chief Medical Officer Exit - TipRanks
Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch - TipRanks
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference - The Manila Times
Senior managers will hold one-on-one meetings in Boston at a Wells Fargo healthcare conference Sept. 8-10. - Stock Titan
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD) - Yahoo Finance
Relmada Therapeutics (RLMD) Slides 4.2% to $4.33 as Clinical-Stage Pressures WeighAdvance Decline Line - vinanet.vn
Relmada Therapeutics Inc. (RLMD) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Relmada Therapeutics Inc. (RLMD) Key Financial Ratios – Valuation, Profitability & More - Value Research
Relmada Therapeutics (RLMD) Slips 0.87% as Shares Defend Support at $4.32Put Call Ratio - dars.gov.et
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Relmada (RLMD) Chart: Moves 0.54% Down to $4.61 in the Latest Session; Levels: Price Remains Between $4.38 Support and $4.84 Resistance on the DayIchimoku Entry - siam.in
Relmada (RLMD) Results Breakdown: The Bottom-Line Figure Beats Its Comparison on the Day; Share Response: Shares Move Lower 0.22% in the Latest ReadingCost Structure Review - vinanet.vn
Relmada (RLMD) Q2 2026 Earnings Call Transcript - AOL.com
616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC - MarketBeat
Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds - Stock Titan
Relmada Therapeutics Earnings Call Highlights NDV-01 Path - TipRanks
Relmada Therapeutics Inc (RLMD) Stock Price, Trades & News - GuruFocus
Mizuho reiterates Relmada stock rating after manufacturing delay By Investing.com - Investing.com UK
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround - Yahoo Finance
Equities Analysts Issue Forecasts for RLMD Q3 Earnings - marketbeat.com
Mizuho reiterates Relmada stock rating after manufacturing delay - Investing.com
Relmada Therapeutics (RLMD) Slides 7.6% to $4.57, Pressuring Key Support LevelMAMA Signal - vinanet.vn
Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Q2 2026 Relmada Therapeutics Inc Earnings Call Transcript - GuruFocus
Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8%Time to Sell? - MarketBeat
Piper Sandler Maintains Relmada Therapeutics(RLMD.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Relmada Therapeutics Q2 Earnings Call Highlights - MarketBeat
Form 8K Relmada Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Relmada Therapeutics (RLMD) Boosts Cash Reserves Ahead of Key IN - GuruFocus
Earnings call transcript: Relmada posts Q2 2026 EPS beat as shares slip - Investing.com Canada
Relmada Q2 2026 earnings: R&D spending rises ahead of planned IND filings - TradingKey
Relmada Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
RLMD: Strong cash position and robust NDV-01 phase II results set stage for late-stage trials in 2026 - TradingView
Relmada Highlights Q2 Results and NDV-01 Pipeline Progress - TipRanks
Relmada Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Relmada Reports Q2 Loss As Cash Balance Reaches $217.7 Million - Quiver Quantitative
Relmada Therapeutics (Nasdaq: RLMD) details Q2 2026 loss and NDV-01 Phase 3 path - Stock Titan
RELMADA THERAPEUTICS, INC. 2Q 2026: Net loss $12.9M, EPS $(0.11) — 10-Q Summary - TradingView
RLMD: Advanced clinical pipeline and robust cash position support operations through 2029 - TradingView
RLMD: Higher net loss driven by R&D ramp-up, but cash position supports key clinical milestones ahead - TradingView
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Press Release: Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - moomoo.com
RLMD Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
Relmada Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Janus Henderson Group PLC Increases Position in Relmada Therapeutics, Inc. $RLMD - MarketBeat
Relmada Therapeutics Appoints Bipin Dalmia as Chief Business Officer to Advance NDV-01 and Corporate Growth - Moomoo
597,409 Shares in Relmada Therapeutics, Inc. $RLMD Bought by Stempoint Capital LP - MarketBeat
BlackRock (NYSE: BLK) discloses 7.0% beneficial stake in Relmada Therapeutics (RLMD) - Stock Titan
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer - Investing News Network
Relmada Therapeutics (RLMD) Names Bipin Dalmia as Chief Business Officer Amid Strategic Growth Focus - GuruFocus
Relmada Therapeutics, Inc. Announces Appointment of Bipin Dalmia as Chief Business Officer - marketscreener.com
Relmada names Bipin Dalmia as chief business officer By Investing.com - Investing.com Nigeria
0.71%
2.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):